🇺🇸 FDA
Patent

US 11098053

Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells

granted A61KA61K31/352A61K35/28

Quick answer

US patent 11098053 (Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells) held by The United States of America, as represented by the Secretary of Agriculture expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary of Agriculture
Grant date
Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/352, A61K35/28, A61K45/06, A61P